About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, November 9th, 2017

The QualityStocks
Daily Stock List


Validian Corp. (VLDI)

Value Penny Stocks, Epic Stock Picks, Hot Stock Profits, StockMarketIntel, TopPennyStockMovers, Profit Sensation, Stock News Now, Damn Good Penny Picks, Penny Picks, PREPUMP STOCKS, Penny Stock Newsletter, Pumps and Dumps, PennyStocks24, and OTC Stock Review reported previously on Validian Corp. (VLDI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Validian Corp. provides software products for public and private enterprises. In essence, the Company is a top innovator in cyber-security technology. Validian develops and markets solutions to protect against the threats of today's digital world. Validian is first-to-market to provide secure storage, access, and transfer of digital information on wired, wireless, or mobile networks over the Internet. Listed on the OTC Markets Group’s OTCQB, Validian is headquartered in Ottawa, Ontario.

The Company’s technology enables the next generation of secure Cloud Computing, Cloud Storage, Distributed Computing and Web Application and WebPortal Access and Usage for desktop and laptop computers, servers, tablets, and Smartphones. Validian’s products include Validian Protect, which embeds its technology into any application.

Validian provides solutions that can undergo customization to the client's business process to ensure end-to-end authenticity, integrity, and custody of high value digital assets. Validian’s corporate mission is to deliver innovative information protection solutions that help government agencies, enterprises, and individuals in lessening the impact of theft, disclosure, non-compliance, or malicious tampering with digital assets.

The Company has extended its core technology, ValidianProtect. It is now the first cyber security technology to cover and seamlessly protect the Complete Life Cycle of Data with secure access, retrieval, transfer, receipt, storage, and usage of digital information on all devices, operating systems, and technology platforms.

Validian redesigned its ValidianProtect technology to include a group of downloadable, re-usable, feature modules. These make it possible for a programmer to quickly and easily add any combination of a substantial number of pre-built, commonly used functions and first-to-market differentiating features to or from any application, thus saving them numerous man-years of previously extra development time.

In August 2017, Validian announced that it recently completed version 3.3 of its inventive cybersecurity technology. This technology seamlessly protects the Complete Life Cycle of Data on all major technology platforms, operating systems, and devices. This completion consisted of minor modifications in addition to the migration and upgrades already completed to Microsoft Windows 10 and the Azure Cloud platform, as well as to recent versions of Google Android, Apple OS and iOS, and to Red Hat Linux.

This week, Validian confirmed that some of the large corporations now in talks with Validian concerning strategic partnership agreements are interested in utilizing the Company’s technology to secure and enhance automotive connectivity and communications. This includes vehicle to vehicle communications.

Validian Corp. (VLDI), closed Thursday's trading session at $0.00675, up 8.00%, on 310,200 volume with 8 trades. The average volume for the last 60 days is 2,183,278 and the stock's 52-week low/high is $0.0056/$0.05.

Bearing Lithium Corp. (BRGRF)

MarketWatch, TradingView, and InvestorsHub reported on Bearing Lithium Corp. (BRGRF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Bearing Lithium Corp. is a mineral exploration and development company concentrating chiefly on lithium. By way of an agreement with Li3 Energy, Inc. (LIEG), Bearing Lithium will acquire an undivided 17.7 percent interest in the advanced-stage Maricunga lithium brine project in Chile. This represents one of the highest-grade development opportunities in the Americas. OTCQB-listed, Bearing Lithium is headquartered in Vancouver, British Columbia.

As of May 9, 2017, the Maricunga Lithium Project has had greater than US$25 million of exploration. All future expenditures through to the delivery of a Definitive Feasibility Study (DFS) are fully-funded by its Joint Venture (JV) partners. Bearing Lithium is now focused on identifying, advancing, and de-risking lithium projects. It carries out all aspects of exploration and development. This is from grassroots prospecting to feasibility studies.

The Company’s other projects include Fish Lake Valley and the HY/Jay project. The Fish Lake Valley Lithium property is in Esmeralda County, Nevada. It consists of a contiguous 1,620-acre package of 81 lode claims.

The HY/Jay project is in the Upper Hyland River area of eastern Yukon. It is in a belt that hosts a number of high-grade gold vein occurrences. This includes the 3Ace property now undergoing exploration by Golden Predator Mining Corp.

The HY claim group was acquired from Freeport McMoRan Exploration in 2011. Freeport retains a 2-per-cent net smelter royalty (NSR) payable to Freeport that can be reduced to a 1-per-cent NSR through a one-time payment of $1 million. In 2011, The HY claim group was then expanded by the addition of the Jay claims via staking.

Bearing Lithium entered into a definitive agreement to acquire Li3 Energy and its interest in the Maricunga Project. Currently, Li3 holds the 17.7 percent interest in the Maricunga Project along with Minera Salar Blanco (MSB) and Lithium Power International Limited at 32.3 percent and 50 percent respectively pursuant to the JV arrangement.

In late September, Bearing Lithium announced that Li3 Energy shareholders overwhelmingly approved the transaction. At a shareholder vote held September 28, 2017 a total of 71.9 percent of shares were voted at the meeting of which 99 percent voted in favor of the transaction. The number of Bearing Lithium shares to be issued under the scheme will be about 16 million shares. Following completion of the transaction, Bearing Lithium will have roughly 46.5 million common shares outstanding, with former Li3 Energy shareholders representing roughly 34 percent of Bearing Lithium’s pro-forma share capital.

In October, Bearing Lithium announced an update to the continuing development work at the Maricunga lithium brine project in Chile, where it holds a 17.7 percent free-carried interest. Stage 1 testing is complete with achievement of 5 percent lithium concentration. Production of first lithium carbonate (Li2CO3) and potash (KCl) samples is expected in Q4 2017. The timelines remain on schedule with a Pre-Feasibility Study in Q4/17 and a Definitive Feasibility Study in H1/18.

Bearing Lithium Corp. (BRGRF), closed Thursday's trading session at $0.65, up 3.36%, on 102,482 volume with 37 trades. The average volume for the last 60 days is 67,929 and the stock's 52-week low/high is $0.35/$1.4111.

Premier Biomedical, Inc. (BIEI)

Information Solutions Group, The Observer, PennyPro, SmallCapVoice, PennyStockRumors.net, Innovative Marketing, PennyStocks24, and FeedBlitz reported on Premier Biomedical, Inc. (BIEI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Premier Biomedical, Inc. is a research-based medical development enterprise. The Company’s emphasis is on discovering, developing, and commercializing medical treatments for a wide array of diseases in humans. This includes unique therapies for breast cancer, and also non-narcotic, all-natural-ingredient, 50-state legal, novel pain management therapies. Premier Biomedical’s research and development (R&D) work is centered in El Paso, Texas. The Company’s business offices are in Western Pennsylvania.

Premier Biomedical has licensed the technology behind several provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. The Company’s Sequential Dialysis Methodology is a novel approach. It eliminates the molecules and proteins from the body that cause disease. Sequential-Dialysis Technique is a methodology for the removal of molecules that are harmful and responsible for causing diseases.

Premier Biomedical’s aim is to discover and develop medical treatments in collaboration with the University of Texas at El Paso (UTEP) and the US Department of Defense, particularly targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer.

The Company’s strategy is to build patentable Sequential Dialysis machines at UTEP, and build patentable antigen-dispersing canisters into the Sequential Dialysis™ Machine. Moreover, Premier’s strategy is to begin a Food and Drug Administration (FDA) application submission, and to approach potential manufacturing and marketing pharmaceutical partners.

The Company is also evaluating strategies to take its Anti-CTLA4 breast cancer treatment through the FDA approval process. It has numerous other continuing projects, in addition to its Anti-CTLA-4-based breast cancer drug.

This past July, Premier Biomedical announced that it terminated the joint venture (JV), Premier Biomedical Pain Management Solutions LLC that was established in September 2016. Premier Biomedical has integrated the pain relief products business into a division of Premier that will continue to develop and market an expanded assortment of natural and synthetic, 50-state legal CBD-based, generalized, neuropathic, and localized pain relief treatment products.

Premier Biomedical has introduced topical skin patches with higher CBD content than previously. The Company also has a higher CBD content topical roll-on.

Early last month, Mr. William A. Hartman, Premier Biomedical’s Chief Executive Officer, interviewed on the Uptick Network Stock Day Podcast with host Everett Jolly. Mr. Hartman provided updates on the upgraded hemp pain relief products, and explained the final resolution of the production issues. He discussed the Biologics Division of the Company’s cancer project and its hiring a reputable agent to help develop potential partners for this Division.

Premier Biomedical, Inc. (BIEI), closed Thursday's trading session at $0.004, down 4.94%, on 5,979,998 volume with 65 trades. The average volume for the last 60 days is 3,501,304 and the stock's 52-week low/high is $0.003/$0.0245.

Viking Energy Group, Inc. (VKIN)

SMS Penny Picks, Greenbackers, SmallCapFinancialWire, Daily Stock Motion, Penny Pick Insider, Penny Stocks VIP, FatCat Stocks, Wall Street Beauties, WINNINGOTC, and UndiscoveredEquities reported earlier on Viking Energy Group, Inc. (VKIN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Viking Energy Group, Inc. is an independent exploration and production corporation whose shares trade on the OTC Markets Group’s OTCQB. The Company targets under-valued assets with realistic appreciation potential. Viking Energy owns oil and gas leases in Kansas, Missouri, and the Province of Alberta. The Company has its head office in New York, New York

Viking Energy, by way of its wholly-owned subsidiary, Mid-Con Petroleum, LLC, owns a working interest in 7 producing oil leases with access to the mineral rights (oil and gas) concerning approximately 800 acres of property in Miami and Franklin Counties in Eastern Kansas. The Company’s working interests (WI’s) in the leases range from 68 percent to 100 percent.

In Missouri, Viking Energy owns a 100 percent W1 (about NRI 83 percent) in 31 leases, with access to the mineral rights (oil and gas) regarding roughly 5,500 acres of property in Cass and Bates Counties.

In the Province of Alberta, Viking Energy has a Joint Venture (JV) with Tanager Energy, Inc. The Company’s investment with Tanager Energy includes a 50 percent WI in the Joffre Project, consisting of 4 oil wells and one water injection well. Tanager Energy’s initial project incorporates the Leduc D-3 B Pinnacle Reef in Central Alberta, which is where the Joffre D-3 Oil Project is positioned (the Joffre Project).

Fundamentally, Viking Energy purchases interests in producing, long-life, low-cost oil properties producing positive cash-flow. The Company is not considering speculative exploration programs. It targets properties with current production and untapped reserves for future benefit. Viking centers on acquiring under-valued, producing properties from distressed vendors or those considered as non-core assets by larger sector participants.

Recently, Viking Energy Group announced that it acquired additional working interests in a variety of oil and gas-related leases in Eastern Kansas. On September 11, 2017, Viking, via a wholly-owned subsidiary, Mid-Con Drilling, LLC, acquired a 90 percent WI in four new oil and gas leases in Anderson County in Eastern Kansas, consisting of roughly 980 acres of property.

On October 5, 2017, Viking Energy Group announced that it acquired additional working interests in various oil and gas-related leases in Kansas. This was its third acquisition in less than 30 days. On October 4th, 2017, Viking, via Mid-Con Drilling, acquired, effective September 1, 2017, an 80 percent WI in six new oil and gas leases in Riley, Geary, and Wabaunsee Counties in Kansas.

Viking Energy Group, Inc. (VKIN), closed Thursday's trading session at $0.1394, even for the day. The average volume for the last 60 days is 12,238 and the stock's 52-week low/high is $0.07/$0.2563.

Avalon Globocare Corp. (AVCO)

OTC Markets, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon’s management draws on their abundance of experience and extensive networks in the biotechnology industry, health care management, as well as academia. Avalon Globocare is based in Freehold, New Jersey. The Company lists on the OTC Markets’ OTCQB.

Avalon Globocare is a premier healthcare management provider and biotechnology developer. Avalon’s commitment is to integrating and managing worldwide healthcare resources. In addition, Avalon, by way of its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities.

The Company’s “Avalon Cell” platform concentrates on cell-based therapies and technologies. Its focus is in the field of in vitro diagnostics, regenerative medicine, and also cancer immunotherapy. Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization internationally.

The “Avalon Rehabilitation” platform is a turnkey, complete suite of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. Regarding Avalon Globocare’s healthcare facility, it presently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

Last week, Avalon Globocare announced that its majority-owned subsidiary, GenExosome Technologies, Inc., acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. At the same time, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, whereby GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

This week, Avalon Globocare announced that it appointed former Congressman, Mr. Billy Tauzin, to the Company’s Board of Directors. Congressman Tauzin has a long and distinguished 36-year elective career. It culminated in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives. The ECC supervises food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.

Avalon Globocare Corp. (AVCO), closed Thursday's trading session at $2.00, even for the day. The average volume for the last 60 days is 596 and the stock's 52-week low/high is $0.51/$5.00.

Freestone Resources, Inc. (FSNR)

InvestorsHub, MarketWatch, 4-Traders, and Amigo Bulls reported on Freestone Resources, Inc. (FSNR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A Technology Development Company, Freestone Resources, Inc. centers on unique solutions for unconventional and conventional oil recovery in economic and environmentally responsible ways. The Company has its oil sand extraction and oil remediation technology. It introduced Petrozene™, which is a pioneering solvent that is making an impact on several aspects of the gas and oil industry. Listed on the OTC Market Group’s OTCQB, Freestone Resources has its corporate headquarters in Dallas, Texas.

The Petrozene solvent is mainly utilized to dissolve paraffin buildup. It is used for pipelines, oil storage tanks, oil sludge build up, de-emulsification, and well treatment. In addition, it is used as a corrosion inhibitor as well as a catalyst in opening up formations, consequently aiding in oil production.

Petrozene’s™ premier flow technology is hydrocarbon-based. This enables a non-contamination use in numerous aspects of oil and gas production and refinement. Petrozene™ improves the viscosity during oil shipment and in storage. Petrozene™ does not have to be removed from the crude before refining.

Moreover, Petrozene™ will enhance the refining process via its ability to liquefy oil sludge, paraffin, and asphaltenes in piping systems. Petrozene™ is made from a byproduct of recycled petroleum-based products. As a result, it will not contaminate the oil reserve to which it is undergoing application.

Pertaining to Oil Transport and Oil Storage Solutions, Petrozene™ has been shown to be an effective dispersant of oil sludge buildup. The research efforts of Freestone Resources and industry partners have shown it to be particularly effective in large, long range oil tankers. With the proper amount of Petrozene™ applied to each shipment of oil, produced results show a significant reduction in oil sludge buildup on the bottom of the tanks.

This week, Freestone Resources announced the signing of a merger agreement under which the Company and Dynamis will combine their businesses in an all-stock transaction. Upon completion of the transaction, Dynamis shareholders are expected to own 75 percent of the new combined entity (not including its existing shares) and Freestone Resources current shareholders will own 25 percent, based on an implied value of $0.195 per share for Freestone’s stock.

The combined entity will have offices in Idaho and Texas. It will also have a joint management team to be announced.

Freestone Resources, Inc. (FSNR), closed Thursday's trading session at $0.078, even for the day. The average volume for the last 60 days is 11,981 and the stock's 52-week low/high is $0.0281/$0.11.

Intrusion, Inc. (INTZ)

Zacks and MarketWatch reported on Intrusion, Inc. (INTZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Intrusion, Inc. is a worldwide provider of entity identification, high speed data mining, cybercrime, and advanced persistent threat detection products. The Company’s product families include TraceCop™ for identity discovery and disclosure, and Savant™ for network data mining and advanced persistent threat detection. Intrusion has its corporate office in Richardson, Texas.

The Company’s products help protect critical information assets. These products do so through quickly detecting, protecting, analyzing and reporting attacks or misuse of classified, private, and regulated information for government and enterprise networks. In 2000, Intrusion launched its first intrusion detection system (IDS) to the enterprise market. It was followed in 2002 by the launch of its intrusion prevention system (IPS).

Intrusion’s TraceCop is a set of Internet monitoring and tracking products. They provide unprecedented capabilities for the identification of malicious and illegal activities based on historical and present Internet usage data. TraceCop helps analysts and investigators significantly decrease the time and complexity for discovering identities, ownership and contact information for computer devices on the Internet.

At the heart of TraceCop lays a premier data collection process. This process continuously collects, processes, as well as stores extensive amounts of historical Internet usage and traffic data into the TraceCop Databases.

The Company’s Savant is a transparent network data capture and analysis solution. Savant brings science into corporate decision making. Savant provides real-time access and insight into an enterprise’s own indisputable and quantifiable network data for more effective, unbiased decision making.

Savant is a purpose-built appliance. It performs an innovative, real-time, transparent data capture and analysis of all content across a company’s network. This includes the “who, what, when and where” of the data from any application.

The Company also has its Secure Taps™. Intrusion offers a set of secure network taps. These enable easy, quick, and strong deployment of any of the Company’s network security appliances. Using a Secure Tap is a first-rate method for deploying network appliances.

This past August, Intrusion announced its financial results for the three and six months ended June 30, 2017. The Company’s Net Loss was $438,000 in Q2 2017, versus a Net Loss of $387,000 in Q2 2016 and $351,000 in Q1 2017. Revenue for Q2 2017 was $1.5 million versus $1.6 million in Q2 2016 and $1.6 million in Q1 2017.

Mr. G. Ward Paxton, Intrusion’s President and Chief Executive Officer, said in August, “We booked $3.9 million of orders in the first half of 2017 compared to $2.4 million in the first half of 2016, a 61 percent increase. Included in the 2017 orders were $0.3 million of initial orders from three new customers with the balance coming from five existing customers. Both new and existing customers that placed first half orders are expected to order additional products and services during the second half of 2017.”

Intrusion, Inc. (INTZ), closed Thursday's trading session at $0.30, down 6.25%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 7,005 and the stock's 52-week low/high is $0.1426/$0.6095.


The QualityStocks
Company Corner


Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.668, up 11.33%, on 306,638 volume with 170 trades. The stock’s average daily volume over the past 60 days is 156,325 and its 52-week low/high is $0.1701/$0.71.

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP) a drug delivery platform innovator, announces it has filed a new patent application with the US Patent and Trademark Office ("USPTO") utilizing the Lexaria DehydraTECHTM technology for delivery of phosphodiesterase type 5 (PDE5) inhibitors - trade names of existing well-known products include ViagraTM (sildenafil) and CialisTM (tadalafil).

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Files Innovative New Patent Application

NetworkNewsWire Announces Publication on the Wide-Ranging Potential of Patented Technology for Improved Bioabsorption

Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC, NSAIDs, Nicotine and Vitamins

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.479, up 10.11%, on 1,636,081 volume with 574 trades. The stock’s average daily volume over the past 60 days is 540,695, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in a proprietary in-house cannabinoid biosynthesis platform capable of producing any of the 90+ "downstream" cannabinoids that occur naturally in the cannabis plant. The publication, titled, "Cannabis Biotechs Could be Big Pharma's Latest M&A Focus," discusses the operations of five cannabis biotech companies, several of which have been part of recent M&A activity. To view the full publication, visit: https://www.networknewswire.com/cannabis-biotechs-big-pharmas-latest-ma-focus/

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

NetworkNewsWire Announces Publication that Highlights Big Pharma's Increasing Interest in Cannabis Biotech Companies

NetworkNewsWire Announces Publication Highlighting Big Pharma's Appetite for M&A Possibilities in Cannabis

Biotech M&A Momentum Attractive for Cannabinoid R&D Space

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.057, up 2.52%, on 1,597,488 volume with 176 trades. The stock’s average daily volume over the past 60 days is 3,122,811, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding Inc. (POTN) announced today that it has entered into a distribution partnership with Total Vapor, Inc., a subsidiary of Vapor Group, Inc. (OTC Pink: VPOR) to distribute Vapor’s revolutionary, electronic herbal grinder, Easy Grinder™, designed to meet the needs of the Medical Marijuana marketplace. The Company will sell Easy Grinder™ directly to consumers via the website of its subsidiary, Diamond CBD, Inc., as well as distribute it via its extensive reseller network.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding, Inc. Announces Distribution Partnership for Easy Grinder™

PotNetwork CEO, Dr. Richard Goulding Updates Shareholders on PublicWire.com

PotNetwork Holding Reports Third Quarter Revenues of $4,444,800.00, Exceeding Second Quarter Results by 29%

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0185, up 0.54%, on 3,883,261 volume with 73 trades. The stock’s average daily volume over the past 60 days is 3,157,096, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. (“MTRAC”, the “Company”) continues to make significant headway with Pegasus Fintech, Inc. on their joint collaboration in the development of a cryptocurrency token that is being developed for the cannabis industry.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout’s MoneyTrac Technology, Inc. and Strategic Partner Pegasus Fintech, Inc. Make Strides with Development of Cryptocurrency Token for Cannabis Industry and Move Closer to Launch of ICO

Global Payout, Inc. is in the Process of Exploring New Partnerships to Take Advantage of the Fast-Growing Logistics Industry

MoneyTrac Technology, Inc. Sells Front Cover of PotSaver’s Premier Los Angeles Edition

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.025854, up 0.21%, on 3,454,729 volume with 169 trades. The stock’s average daily volume over the past 60 days is 4,455,246 and its 52-week low/high is $0.0181/$0.127.

Marijuana Company of America Inc. (MCOA), an innovative hemp and cannabis corporation, is pleased to announce that it has completed its financing of $800,000 in cash and 15 million shares of the Company's common stock in full satisfaction of the amended terms of the joint venture agreement with Bougainville Ventures, Inc. ("BV").

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Marijuana Company of America Completes Financing for Cultivation Facility in Washington State

NetworkNewsBreaks – Marijuana Company of America (MCOA) Delivers Distinctive Cannabis Investment Opportunities

Marijuana Company of America (MCOA) Delivers with Unique Marketing, Distribution Platforms

Zinc One Resources, Inc. (TSX-V: Z) (OTC: ZZZOF) (FSE: RH33)

The QualityStocks Daily Newsletter would like to spotlight Zinc One Resources, Inc. (ZZZOF). Today, Zinc One Resources, Inc. closed trading at $0.3492, off by 4.49%, on 57,298 volume with 23 trades. The stock’s average daily volume over the past 60 days is 53,980 and its 52-week low/high is $0.011/$0.81.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Zinc One Resources Inc. (TSX-V:Z) (OTC:ZZZOF) (FSE:RH33), a client of NNW specializing in the acquisition, exploration and development of advanced zinc assets in mining-friendly jurisdictions. The publication, titled, "Producers Aim to Address Growing Global Zinc Deficit amid Price Surge, Rising Demand," highlights zinc mining companies working to extract the highly prized commodity that is vital to the world's diverse infrastructure and power generation sectors. To view the full publication, visit: https://www.networknewswire.com/producers-aim-address-growing-global-zinc-deficit-amid-price-surge-rising-demand/

Zinc One Resources, Inc. (TSX-V: Z) (OTC: ZZZOF) (FSE: RH33) is a Vancouver, Canada-based company focused on the acquisition, exploration and development of prospective and advanced zinc projects in mining friendly jurisdictions. Zinc One's key assets are the Bongará Zinc Mine and Charlotte-Bongará Zinc-Oxide Project in north-central Peru. Historical production of the Bongará Mine, which was mined from 2007-2008 until a fall in zinc prices shut it down, revealed greater than 20 percent zinc grades and recoveries over 90 percent, all from surface mining. Bongará's high grade zinc mineralization is considered a rare situation and one that Zinc One management is poised to explore further. The neighboring Charlotte-Bongará Zinc-Oxide Project has multiple at-surface, high-grade drill intercepts providing numerous drill targets.

Zinc One controls both zinc-oxide mine projects, making it the first time a single operator has been in control of the two locations, giving the company a unique opportunity to delineate a substantial high-grade, zinc-oxide resource along a 4 kilometres-long trend. A previous operator produced 55.1 million pounds of zinc, running at 358 tonnes a day. Zinc One has access to all data and technical work dating back to the 1990s and controls a third zinc prospect located in central Peru as part of its portfolio.

The company has also received approval from Peru's Ministry of Energy and Mines to suspend the mine closure at the Bongará location, which allows Zinc One to utilize the current Environmental Impact Assessment attached to the project for current and future permitting. This critical approval allows the company to take another important step forward in its plans to reopen production at the Bongará zinc-oxide project. Zinc One's project locations involve open pit/surface mining, requiring less infrastructure and a much better cost ratio than traditional underground mines.

Zinc One is managed by a proven team of exploration geologists and engineers with extensive experience in constructing and operating successful mining operations. The company's business strategy includes restarting production at the Bongará Zinc-Oxide Mine with exploration of targets along a 6-kilometer strike as well as exploring the Charlotte Bongará Zinc-Oxide Project.

World stockpiles of zinc are at multiyear lows while demand continues to be strong. In 2016, zinc demand became greater than the available supply for the first time in a decade. Zinc is essential for rustproofing steel and is used in a variety of infrastructures. It's also used to produce batteries, fertilizers, paints, plastics, cosmetics and multivitamins. The International Zinc Association estimates that zinc could save the world over $300 billion annually in direct corrosion costs and another $300 billion annually in indirect costs. Zinc is an invaluable base metal and a strategic priority for many industries. Disclaimer

Zinc One Resources, Inc. Blog

Zinc One Resources, Inc. News:

NetworkNewsWire Announces Publication Highlighting Growing Global Zinc Deficit Amid Rising Demand

NetworkNewsWire Announces Publication Discussing Several Stocks Gearing Up to Fill Zinc Shortage

NetworkNewsWire Announces Publication Highlighting Zinc Producers Competing to Meet Rising Demand

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.47, off by 7.84%, on 68,860 volume with 18 trades. The stock’s average daily volume over the past 60 days is 37,905 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB), an advanced digital software company focused on helping to improve the bottom line and overall cost effectiveness of hospitals, announces that it has signed a five-year revenue agreement with a nationally recognized institution listed among the country's "Top 100 Hospitals." The agreement underscores the value and power that ORHub brings to the market by working hand-in-hand with medical industry professionals to dramatically improve operating margins and hospital economics.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. (ORHB) Signs 5-year Revenue Agreement with Nationally Recognized "Top 100" Hospital

ORHub, Inc. (ORHB) Warrants Set to Expire on December 31, 2017

ORHub, Inc. Announces Additional Deployment of Disruptive Surgical Information Software at Three Leading Hospitals in Southern California


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



MarketClub Analysis
(CREG) +195.28%


Trader Power News
(RTNB) +144.44%


(OTIC) +83.04%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251